Protalix BioTherapeutics (PLX) Misses Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.36 +2.61%
EPS Growth %: +400.0%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +400.0%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.25), $0.17 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $6.43 million versus the consensus estimate of $8.3 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
- Unum Group (UNM) PT Raised to $94 at UBS on Second LTC Deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
